CORRESP 1 filename1.htm

 

 

   

 

 

May 12, 2015

 

Securities and Exchange Commission

100 F. Street, NE

Washington, D.C. 20549

 

Re:DelMar Pharmaceuticals, Inc.
  Registration Statement on Form S-1
  File No. 333-203357
   

 

 

Ladies and Gentlemen:

 

Pursuant to Rule 461 of the General Rules and Regulations of the U.S. Securities and Exchange Commission under the Securities Act of 1933, as amended, Maxim Group LLC and Roth Capital Partners, LLC, as joint book running managers and representative of the underwriters, hereby request acceleration of the effective date of the above-referenced Registration Statement so that it will become effective at 4:00 p.m., Washington D.C. time, on Wednesday May 13, 2015, or as soon thereafter as practicable.

 

The following is supplemental information supplied under Rule 418(a)(7) and Rule 460 under the Securities Act of 1933:

 

(i) Date of preliminary prospectus: May 7, 2015
(ii) Dates of distribution:  May 8 – May 11, 2015
(iii) Number of prospective underwriters and dealers to whom the preliminary prospectus was furnished: 4
(iv) Number of prospectuses so distributed: approximately 580

 

The undersigned confirms that it has complied with and will continue to comply with, and it has been informed or will be informed by participating dealers that they have complied with or will comply with, Rule 15c2-8 promulgated under the Securities Exchange Act of 1934, as amended, in connection with the above-referenced issue.

 

 

 

Very truly yours,

 

 

MAXIM GROUP LLC

 

 

/s/ Clifford A. Teller

_______________________________

Name: Clifford A. Teller

Title: Executive Managing Director,

Head of Investment Banking

 

 

 

 

ROTH CAPITAL PARTNERS, LLC

 

 

/s/ Aaron M. Gurewitz

_______________________________

Name: Aaron M. Gurewitz

Title: Head of Equity Capital Markets